Research Seminars

About

Research Seminars gather a small number (20 to 100) of well-established and preferably young investigators to address scientific topics in depth and help break new ground. Research Seminars take place over two days in easy-to-reach European cities. They are scientific Seminars involving recently published work and research in progress. Participation is fully supported by the budget granted by the ERS.

New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine

Download all media

What are the main mechanisms of oncogenic addiction? Joanna Chorostowska (Poland)
Are KRAS mutations druggable? Marina Garassino (Italy)
How does the cancer immunity circle operate (or dysoperate)? Daan Hurkmans (Netherlands), Joachim Aerts (Netherlands)
Session 1: From molecular alterations to cancer immunity in NSCLC - Panel discussion Joanna Chorostowska (Poland), Marina Garassino (Italy), Daan Hurkmans (Netherlands)
Molecular diagnosis for oncogenic addictions Patrick Pauwels (Belgium)
When and how to identify resistance mechanisms to targeted therapies Nicolas Girard (France)
Predictive biomarker of immune checkpoint inhibitors efficacy Thierry Berghmans (Belgium), Luis Paz-Ares (Spain)
Session 2: From molecular target to molecular resistance in NSCLC - Panel discussion Patrick Pauwels (Belgium), Nicolas Girard (France), Luis Paz-Ares (Spain)
Therapeutic strategy for EGFR driven NSCLC Jacques Cadranel (France)
Therapeutic strategy for ALK/ROS driven NSCLC Jan Van Meerbeeck (Belgium)
Therapeutic strategy for other oncogenic drivers David Planchard (France)
Session 3: From molecular addiction to therapeutic strategy in NSCLC - Panel discussion Jacques Cadranel (France), Jan Van Meerbeeck (Belgium), David Planchard (France)
From anti-PD1/L1 inhibitors to new immunotherapies Thierry Berghmans (Belgium)
Which immunotherapy for which patients? Lizza Hendriks (Netherlands)
Combination therapy in the era of immunotherapy Anne-Marie Dingemans (Netherlands)
Session 5: From PD1/PD-L1 monotherapy in selected patients to PD1/PD-L1 combo for all NSCLC - Panel discussion Thierry Berghmans (Belgium), Lizza Hendriks (Netherlands), Anne-Marie Dingemans (Netherlands)